Amna Kamil Leads Systematic Review on Factor Xa Inhibitors for Cancer-Associated VTE
Amna Kamil, MS5 at JSMU (Jinnah Sindh Medical University) posted on LinkedIn:
”Publication Alert
Alhamdulillah
Thrilled to announce that my first Systematic Review and Meta-analysis has been published as First Author in Clinical and Applied Thrombosis/Hemostasis (SAGE Journals)
Why this research matters:
Cancer patients face a much higher risk of developing venous thromboembolism (VTE) – a major cause of morbidity and mortality. Traditional anticoagulants (like LMWH or VKAs) have limitations, leading to growing interest in Factor Xa inhibitors (DOACs such as apixaban and rivaroxaban).
What we found:
Factor Xa inhibitors significantly reduced the risk of VTE compared to placebo.
However, they were also linked to a higher risk of major bleeding.
The balance between benefit and risk highlights the importance of individualized patient selection and the need for further large-scale trials.
This work contributes to ongoing discussions on optimizing thromboprophylaxis in high-risk cancer patients, aiming for safer and more effective clinical decision-making.
This marks a special milestone in my research journey. Grateful to my incredible co-authors and mentors for their constant support and teamwork throughout this process.”
Read the full article here.
Title: “Efficacy of Factor Xa Inhibitors Versus Placebo in Thromboprophylaxis for Cancer-Associated Thromboembolism: A Systematic Review and Meta-analysis”
Authors: Amna Kamil, Sandhiya Prem Kumar, Rumaisa Zulfiqar, Eiman Araib, Bibi Samia Khan, Muhammad Saad Khan, Muhammad Mohsin Khan, Umaimah Naeem, Aminath Waafira
Stay updated with Hemostasis Today.
-
Jan 9, 2026, 12:17Louise St Germain Bannon Invites You to Self-Nominate for the ISTH Council
-
Jan 9, 2026, 09:25Emma Groarke Shares A Comprehensive Review on VEXAS Syndrome
-
Jan 9, 2026, 09:13Anirban Sen Gupta Presents PlateChek
-
Jan 9, 2026, 08:58Oscar Pena Shares KDIGO 2026 Update: 5 Critical Changes for Anemia in CKD Management
-
Jan 9, 2026, 07:38Bartosz Hudzik on Subacute Coronary Occlusions: Navigating the Gray Zone in CAD Care
-
Jan 9, 2026, 07:27Gregory Piazza on The Role of D-Dimer in VTE Evaluation
-
Jan 9, 2026, 07:19Emmanuel J Favaloro Shares the 1st Article in a VWD Series Marking the 100-Year Anniversary
-
Jan 9, 2026, 07:07Taylor Robichaux on Recombinant ADAMTS13 Therapy in cTTP
-
Jan 9, 2026, 06:25Sara Ng: VTE Continues to Plague Modern Oncology